Gut Microbiome Modulation for Immune Checkpoint Response
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need to enhance the efficacy of immune checkpoint blockade therapy in cancer treatment, as it is associated with substantial toxicity and only a subset of patients benefit, while the role of the microbiome in therapeutic responses remains unclear.
Innovation Solution
Administering specific populations of bacteria from families such as Ruminococcaceae, Clostridiaceae, and Lachnospiraceae, either as live bacterial products or bacterial spores, to modulate the gut microbiome, thereby increasing CD8+ T lymphocytes and innate effector cells, and decreasing suppressive myeloid cells, enhancing the immune response against cancer.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If immune checkpoint blockade therapy is administered to all patients, then more patients may benefit from treatment, but toxicity increases and overall response rates remain modest
Solution Approach 1:
The patent introduces the microbiome (specifically bacteria from families Ruminococcaceae, Clostridiaceae, and Lachnospiraceae) as an intermediary to enhance the efficacy of immune checkpoint blockade therapy. These bacterial populations modulate the immune system to improve patient response to treatment without increasing toxicity, effectively acting as a mediator between the therapy and the patient's immune response.
2Object-affected harmful factors
If only a subset of patients receive immune checkpoint blockade therapy, then toxicity is reduced, but the number of patients who benefit is limited
Solution Approach 1:
The microbiome-modulating bacteria serve as a selective enhancer that can be administered to identify or prepare patients who will respond well to immune checkpoint blockade therapy. This allows clinicians to target therapy more precisely to patients likely to benefit, reducing unnecessary toxicity in non-responders while increasing the number of patients who achieve a positive response.
Solution Approach 2:
The patent employs preliminary modulation of the microbiome using specific bacterial populations before administering immune checkpoint blockade therapy. This preliminary action prepares the patient's immune system in advance, creating a favorable microbial profile that predicts and enhances response to subsequent therapy, thereby identifying suitable candidates before treatment begins.
3Loss of information
If the role of the microbiome in therapeutic responses is investigated, then understanding of treatment variation improves, but translational knowledge gaps remain
Solution Approach 1:
The patent bridges the translational gap by using specific bacterial populations as a tangible, manufacturable intervention based on microbiome research findings. Rather than停留在理论阶段, the invention provides a concrete probiotic composition that can be produced and administered clinically, translating the understanding of microbiome-treatment interactions into an actionable therapeutic strategy.
Data Source
AI summary
Provided herein are methods and compositions for the treatment of cancer by modulating the microbiome to enhance the efficacy of immune checkpoint blockade. The microbiome may be modulated by the administration of butyrate and/or butyrate-producing bacteria. Also provided herein are methods of determining a response to an immune checkpoint inhibitor by identifying if a subject has a favorable microbial profile.